Growth Metrics

Neogenomics (NEO) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$27.1 million.

  • Neogenomics' Income towards Parent Company fell 5327.98% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 4598.09%. This contributed to the annual value of -$78.7 million for FY2024, which is 1050.61% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Income towards Parent Company is -$27.1 million, which was down 5327.98% from -$45.1 million recorded in Q2 2025.
  • Neogenomics' 5-year Income towards Parent Company high stood at $75.9 million for Q2 2021, and its period low was -$49.4 million during Q1 2022.
  • Moreover, its 5-year median value for Income towards Parent Company was -$24.3 million (2023), whereas its average is -$22.0 million.
  • Over the last 5 years, Neogenomics' Income towards Parent Company had its largest YoY gain of 121185.52% in 2021, and its largest YoY loss of 89577.63% in 2021.
  • Neogenomics' Income towards Parent Company (Quarter) stood at -$41.8 million in 2021, then soared by 45.67% to -$22.7 million in 2022, then surged by 36.85% to -$14.3 million in 2023, then dropped by 6.97% to -$15.3 million in 2024, then crashed by 77.04% to -$27.1 million in 2025.
  • Its Income towards Parent Company stands at -$27.1 million for Q3 2025, versus -$45.1 million for Q2 2025 and -$25.9 million for Q1 2025.